| Bioactivity | BIIB-028 is an orally active inhibitor for heat shock protein 90 (Hsp90). BIIB-028 targets the ATP-binding site of Hsp90, disrupts the function of Hsp90, leads to the degradation of client proteins, that are crucial for cancer cell survival and proliferation[1][2]. |
| CAS | 911398-13-5 |
| Formula | C19H21ClN5O5P |
| Molar Mass | 465.83 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Soga S, et al., Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development. Curr Pharm Des. 2013;19(3):366-76. [2]. Rahimi M N. Investigating cyclic peptide inhibitors of heat shock protein 90 (Hsp90): from design and synthesis to cellular drug delivery[D]. UNSW Sydney, 2020. |
BIIB-028
CAS: 911398-13-5 F: C19H21ClN5O5P W: 465.83
BIIB-028 is an orally active inhibitor for heat shock protein 90 (Hsp90). BIIB-028 targets the ATP-binding site of Hsp90
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.